Protect access to abortion medication

In anticipation of a Texas federal district court ruling suspending the Food and Drug Administration’s approval of mifepristone, many Alliance states began securing stockpiles of abortion medication.
Reproductive Freedom Alliance Responds to Supreme Court Ruling on Mifepristone
  • Alliance
    •
  • Alliance
    •  May 14, 2026

    Reproductive Freedom Alliance Responds to Supreme Court Ruling on Mifepristone

    “Today’s Supreme Court decision brings a measure of relief, but not a resolution. While access to mifepristone through telehealth and certified pharmacies remains in place for now, the continued legal uncertainty underscores how fragile reproductive freedom remains.”
    What to know about mail-order mifepristone as Shapiro urges Supreme Court to maintain access
  • Pittsburgh Post-Gazette
  • Pennsylvania
    •
  • Pittsburgh Post-Gazette
  • Pennsylvania
    •  May 7, 2026 • Hanna Webster

    What to know about mail-order mifepristone as Shapiro urges Supreme Court to maintain access

    Hanna Webster

    Mifepristone, a drug used for miscarriage management and to end pregnancy, has been thrust again into the national spotlight — this time with response from Gov. Josh Shapiro.
    Governors React to Supreme Court Ruling on Mifepristone
  • Alliance
    •
  • Alliance
    •  May 4, 2026

    Governors React to Supreme Court Ruling on Mifepristone

    “The Reproductive Freedom Alliance is relieved that the Supreme Court has temporarily restored access to mifepristone, ensuring patients can receive care without unnecessary barriers.”
    Governors Condemn Fifth Circuit Ruling on Mifepristone: ‘A Major Attack on Every Patient in Every State.’
  • Alliance
    •
  • Alliance
    •  May 2, 2026

    Governors Condemn Fifth Circuit Ruling on Mifepristone: ‘A Major Attack on Every Patient in Every State.’

    “Today, the Fifth Circuit Court of Appeals delivered a devastating blow to patients across America, ordering the FDA to re-instate an in-person dispensing requirement for a medication that has been safely used by millions of people for over 25 years. This disastrous decision impacts patients in all 50 states, including states led by the governors of the Reproductive Freedom Alliance, where abortion is legal and protected.
    Washington law will make it easier for state to distribute its abortion pill stockpile
  • Washington State Standard
  • Washington
    •
  • Washington State Standard
  • Washington
    •  March 14, 2026 • Jake Goldstein-Street

    Washington law will make it easier for state to distribute its abortion pill stockpile

    Jake Goldstein-Street

    A state law signed Saturday seeks to ensure remaining pills the state has on hand are easier to access and use. Before Senate Bill 5917, the state needed to sell its mifepristone pills for at least the purchase price, plus an extra $5 fee per dose.
    RFA Affirms the Safety of Mifepristone to Senate HELP Committee
  • Alliance
    •
  • Alliance
    •  January 14, 2026

    RFA Affirms the Safety of Mifepristone to Senate HELP Committee

    The Reproductive Freedom Alliance (RFA)–a nonpartisan coalition of 23 governors committed to protecting and expanding reproductive freedom–today submitted a statement for the record to the Chair and Ranking Member of the Senate Committee on Health, Education, Labor, and Pensions (HELP). The statement is in connection with the HELP Committee hearing on medication abortion on January 14 and calls on lawmakers to reject politicized, non-peer reviewed claims that contradict decades of scientific evidence.
    Reproductive Freedom Alliance Urges FDA to Uphold Science on Mifepristone
  • Alliance
    •
  • Alliance
    •  October 14, 2025

    Reproductive Freedom Alliance Urges FDA to Uphold Science on Mifepristone

    The Reproductive Freedom Alliance — a nonpartisan coalition of 23 governors committed to protecting and expanding reproductive health care — today submitted a letter to the U.S. Department of Health and Human Services (HHS) and Food and Drug Administration (FDA) urging Secretary Robert F. Kennedy Jr. and Commissioner Makary to reject political interference and stand by decades of scientific evidence supporting mifepristone’s safety and effectiveness.
    Gov. Pritzker Signs Bills to Fortify Reproductive Health Care in Illinois
  • Illinois
    •
  • Illinois
    •

    Gov. Pritzker Signs Bills to Fortify Reproductive Health Care in Illinois

    Gov. Pritzker signed an expanded state shield law (HB3637) protecting health care providers from discipline for providing health care services that are lawful in Illinois, and HB3709 which requires public colleges and universities to offer contraception and medication abortion if they have an on-campus pharmacy or student health center.
    Challenging Mifepristone Restrictions
  • Minnesota
    •
  • Minnesota
    •  August 22, 2025

    Challenging Mifepristone Restrictions

    In August 2025, Minnesota joined a multi-state coalition in filing a petition to the U.S. Food and Drug Administration to remove medically unnecessary, burdensome restrictions on mifepristone, a safe and effective abortion medication. The petition states that “given mifepristone’s well-established safety record in the United States over the last 25 years, its critical importance for abortion care and miscarriage management in Petitioner States, and the undue burdens the Mifepristone REMS Program places on patient access and the health care delivery system, the Mifepristone REMS Program should be removed in its entirety, or alternatively, FDA should exercise its discretion not to enforce the Mifepristone REMS Program (or elements thereof) in Petitioner States.”
    Challenging Mifepristone Restrictions
  • Oregon
    •
  • Oregon
    •  August 22, 2025

    Challenging Mifepristone Restrictions

    In August 2025, Oregon co-led a multi-state coalition in filing a petition to the U.S. Food and Drug Administration to remove medically unnecessary, burdensome restrictions on mifepristone, a safe and effective abortion medication. The petition states that “given mifepristone’s well-established safety record in the United States over the last 25 years, its critical importance for abortion care and miscarriage management in Petitioner States, and the undue burdens the Mifepristone REMS Program places on patient access and the health care delivery system, the Mifepristone REMS Program should be removed in its entirety, or alternatively, FDA should exercise its discretion not to enforce the Mifepristone REMS Program (or elements thereof) in Petitioner States.”